Novo Nordisk (NYSE: NVO) has become one of the most valuable healthcare stocks in the world due in large part to Ozempic, its diabetes drug that has also been effective in helping people lose weight. One challenge for investors and analysts, however, is predicting just how much revenue it could bring in at its peak. As new studies emerge involving the drug, there are new possible benefits uncovered relating to the use of Ozempic.

Recently, there was yet another study on Ozempic, which could unlock a huge opportunity for the drug. And it could mean billions more in additional revenue for the healthcare company.

The impact Ozempic and other glucagon-like peptide 1 (GLP-1) drugs have had in curbing appetite for people has been so effective that researchers are wondering what effects it may have on the brain. 

Continue reading

Source Fool.com